Broadly neutralizing antibodies against HIV successfully inhibit further infection of HIV.
A life saving treatment against HIV infection is not a dream now; it could be reality tomorrow, as researchers from National Institute of Allergy and Infectious Diseases (NIAID) USA have developed antibodies which are successful in inhibiting HIV from infecting new human CD4 cells.
Broadly neutralizing antibodies (bNAbs) are group of antibodies PGT121, VRC01 and VRC03.
These antibodies were administered to HIV patients who have discontinued drug therapy for various reasons including side effects of prolonged use and were found to keep viral load under control.
In an experimental model these antibodies (bNAbs) prevented HIV from infecting new CD4 cells derived from HIV negative donors in an invitro experimental model. These antibodies can be used in treating individuals who stop taking antiretroviral drugs, bNAbs can reduce the load of antiretroviral drugs and their side effects when combined with drug therapy.
A life saving treatment against HIV infection is not a dream now; it could be reality tomorrow, as researchers from National Institute of Allergy and Infectious Diseases (NIAID) USA have developed antibodies which are successful in inhibiting HIV from infecting new human CD4 cells.
Broadly neutralizing antibodies (bNAbs) are group of antibodies PGT121, VRC01 and VRC03.
These antibodies were administered to HIV patients who have discontinued drug therapy for various reasons including side effects of prolonged use and were found to keep viral load under control.
In an experimental model these antibodies (bNAbs) prevented HIV from infecting new CD4 cells derived from HIV negative donors in an invitro experimental model. These antibodies can be used in treating individuals who stop taking antiretroviral drugs, bNAbs can reduce the load of antiretroviral drugs and their side effects when combined with drug therapy.
No comments:
Post a Comment